International, Multicentre, Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Extension of PRISM Study I10E-1302"
Phase of Trial: Phase III
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Immune globulin (Primary)
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy
- Focus Therapeutic Use
- Acronyms PRISM2
- Sponsors LFB Biotechnologies
- 02 Aug 2017 This study has been discontinued in Germany as per European Clinical Trials Database record.
- 01 Aug 2017 This study has been discontinued in Spain as per European Clinical Trials Database record.
- 12 Sep 2016 Planned End Date changed from 1 Apr 2018 to 1 Jun 2018.